Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Baden-Baden – page 69

1 153 clinical trials in Baden-Baden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Baden-Baden at a glance
1 153
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 153 trials in Baden-Baden

Open in trial search

Cough

Not recruiting

Study on the Effectiveness and Safety of Camlipixant for Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Endometrial cancer

Not recruiting

Study Comparing Sentinel Node Policy with Current Staging Protocols in Early Stage Endometrial Cancer Using Patent Blue, Technetium (99mTc) Rheniumsulfide, and Indocyanine Green

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Indocyanine Green
  • Sponsor:Centre Oscar Lambret

Asplenia

Not recruiting

Study on the Safety and Immune Response of Meningococcal B Vaccines in Adults with Asplenia: Bexsero, Trumenba, and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Neisseria Meningitidis Group B Fhbp Protein Subfamily A
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neoplasm+2

Not recruiting

Study of ELVN-002 with Trastuzumab and Chemotherapy for Patients with Advanced HER2+ Solid Tumors, Colorectal Cancer, and Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Enliven Therapeutics Inc.

Retinoblastoma

Not recruiting

Study on Adjuvant Treatment for Unilateral Retinoblastoma with Vincristine Sulfate and Drug Combination in Patients After Primary Eye Removal

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Study on Durvalumab for Patients with Poor General Condition and Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Glioblastoma

Not recruiting

Study on Durvalumab and Radiation Therapy for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oncopole Claudius Regaud

Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Baden-Baden

What the registry says about research in the country

01 Eye Diseases and Ocular Physiology

Clinical research in Baden-Baden includes studies focused on eye diseases and ocular physiological phenomena, with attention on atrophic age-related macular degeneration. These trials are exploring ways to slow disease progression and better understand vision-related decline.

  • Testing a new approach for geographic atrophy linked to AMD
  • Evaluating treatment effectiveness in progressive retinal disease

The goal is to improve care for patients facing gradual loss of vision through more effective targeted therapies.

02 Neoplasms in Breast Cancer Research

A major part of the clinical trial activity in the city centers on breast cancer, including HER2+, HR+/HER2-, and triple-negative early breast cancer. These studies are examining new treatment combinations to strengthen disease control and improve long-term outcomes.

  • Assessing new therapy combinations for HER2+ early breast cancer
  • Comparing treatment strategies in HR+/HER2- early breast cancer
  • Studying options for triple-negative early breast cancer

Research in this area is aimed at improving response rates and reducing the chance of recurrence after initial treatment.

03 Hemic and Lymphatic Diseases

Trials in hematologic malignancies are investigating new strategies for patients with high-risk chronic lymphocytic leukemia. The focus is on whether newer drug combinations can offer stronger disease control than current standard approaches.

  • Evaluating combination treatment for high-risk CLL
  • Studying outcomes in patients with adverse genetic risk factors

These studies are designed to improve progression control and support more personalized treatment choices.

04 Ovarian and Gynecologic Cancer

Another active research area involves advanced ovarian cancer and related gynecologic cancers, including fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The trials are examining treatment strategies for patients with no visible residual tumor after surgery.

  • Studying maintenance approaches in HRD-positive high-grade ovarian cancer
  • Evaluating recurrence prevention after primary tumor debulking

These efforts aim to extend recurrence-free survival and refine post-surgical treatment planning.

05 Personalized Oncology in Early Breast Cancer

Several studies are exploring personalized cancer therapy for early-stage breast cancer, using treatment selection to match individual risk profiles. This includes approaches that combine targeted medicine, endocrine therapy, and other systemic treatments.

  • Testing personalized treatment for intermediate- to high-risk HR+/HER2- breast cancer
  • Comparing targeted therapy with standard adjuvant care
  • Improving invasive disease-free survival in early cancer care

In Baden-Baden, this line of research reflects a broader move toward more tailored and effective cancer treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.